The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, Marjan Farid, MD; Beeran Meghpara, MD; and John Hovanesian, MD; review the role of neuromodulation in the pathogenesis of dry eye disease (DED). Additionally, the expert panel discusses a case study of a typical patient presenting with DED and reviews current and newly available treatment options.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Describe the neural network that monitors the ocular surface environment and regulates tear secretion
• Assess the mechanisms of action of neuromodulation therapeutics in DED
• Evaluate current and emerging therapeutics for DED
• Identify clinical applications and patient selection for neuromodulation therapies in DED

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from Alcon Vision, LLC.

Faculty

Marjan Farid, MD
Professor of Ophthalmology
Director of Cornea, Cataract, and Refractive Surgery
Vice-Chair of Ophthalmic Faculty
University of California, Irvine
Irvine, CA

Disclosures: Marjan Farid, MD, has no financial relationships to disclose.

John Hovanesian, MD
Clinical Faculty
UCLA Jules Stein Eye Institute
Los Angeles, CA

President
Harvard Eye Associates
Laguna Hills, CA

Disclosures: Grant/Research Support: AcuFocus, Aerie, Alcon, Allergan, Bausch + Lomb, Cord, EyePoint, Glaukos, Imprimis, Johnson & Johnson Vision, Novartis, Omeros, On Point Vision, Research Insight, Sight Sciences, Sun Pharma, Zeiss; Consultant: AcuFocus, Aerie, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Ophthalmics, BlephEx, Bruder Healthcare, BVI, Centricity Vision, Cloudbreak Therapeutics, Cord, CorneaGen, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, GSK, Hasa Optix, Horizon Therapeutics, Hoya, Imprimis, Johnson & Johnson Vision, Kala, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis, Oyster Point Pharma, Rayner, Research Insight, Sensimed, SightLife, Sun Pharma, Tarsus, TearLab, Thea Pharma, Touch Ophthalmology, Trefoil Therapeutics, Vindico Medical Education, Visus, Zeiss; Other: Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, Apellis, Bausch + Lomb, BlephEx, Bruder Healthcare, BVI, Cloudbreak Therapeutics, Cord, CorneaGen, Crisper, Dompe, Eyedetec, EyePoint, Glaukos, Glint Pharma, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Hasa Optix, Horizon Therapeutics, Hoya, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, Orasis, Research InSight, RxSight, Sight Sciences, SightLife, Slack Books, Sun Pharma, Tarsus, Tear Clear, Trefoil Therapeutics, Versant Ventures and its investments, Visionary Ventures Fund 1 and 2 and its investments, Visus, Zeiss.

Beeran Meghpara, MD
Clinical Assistant Professor of Ophthalmology
Thomas Jefferson University School of Medicine
Director of Refractive Surgery
Wills Eye Hospital
Philadelphia, PA

Disclosures: Consultant: Alcon, Allergan, BioTissue, Dompé, Glaukos, Gore, Johnson & Johnson Vision, Kala, Oculus, Orasis, Sight Sciences, Sun Pharma, Tarsus, Théa, Zeiss; Speakers Bureau: Alcon,

Dompé, Johnson & Johnson Vision, Sun Pharma.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on agents targeting neuromodulation in dry eye disease, go https://www.gotoper.com/courses/the-neural-network-exploring-the-role-of-neuromodulation-in-dry-eye-disease-management-6q0a

Release Date

July 31, 2025

Expiration Date

July 31, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.